Support

Quick links
Frequently asked questions - categories
Ask a question
Contact Us
+1

TAG-72 / CA72.4 Monoclonal Mouse Antibody (B72.3 + CA72/733)

Recognizes an oncofetal antigen of 220 kDa, identified as a tumor-associated glycoprotein (TAG-72) with properties of a mucin.

Product Attributes

Antibody number

0734

Reactivity (target)

TAG-72, CA72.4

Antibody type

Primary

Host species

Mouse

Clonality

Monoclonal

Clone

B72.3 + CA72/733

Isotype

IgG's

Molecular weight

220 kDa

Synonyms

CA72.4, Tumor associated glycoprotein 72

Human gene symbol

tag-72

Entrez gene ID

182875

SwissProt

Not Known

Unigene

Not Known

Immunogen

TAG-72 protein (B72.3 & CA72/733)

Cellular localization

Cytoplasmic, Membrane/cell surface

Species reactivity

Cow, Dog, Human, Rat

Applications

Immunofluorescence, Flow cytometry

Application notes

Flow Cytometry 0.5-1 ug/million cells/0.1 mL, Immunofluorescence 1-2 ug/mL

Positive control

Jurkat cells, Breast or lung carcinoma.

Shipping condition

Room temperature

Storage Conditions

Store at 2 to 8 °C, Protect fluorescent conjugates from light, Note: store BSA-free antibodies at -10 to -35 °C

Shelf life

Guaranteed for at least 24 months from date of receipt when stored as recommended

Regulatory status

For research use only (RUO)

Research areas

Cancer

Cell/tissue expression

Epithelial cells

Tumor expression

Lung cancer

Certificates of Analysis (COA)

Request COA
Conjugation
Size
Catalog #
price
Qty
50 uL
100 uL
250 uL
500 uL
Clear selection
Add to wishlist
ADD TO CART
(Please select quantity above )

Wishlist updated! View wishlist

Shipping, Handling & Tax (CA only) not included in price. Learn more

Tax is assessed in the state of California. All fees will be calculated during checkout based on your shipping information and are subject to change.

SPECIAL - Order 5 or more and receive 10% off.

Request a Bulk Quote

Product Description

Recognizes an oncofetal antigen of 220 kDa, identified as a tumor-associated glycoprotein (TAG-72) with properties of a mucin. This MAb defines the mucin-carried sialylated-Tn epitope. TAG-72 is usually expressed by adenocarcinomas, but is negative in mesotheliomas. Studies have reported that this antibody has 80% sensitivity and 93% specificity for pulmonary adenocarcinoma. Therefore, TAG-72 is a useful marker to distinguish between mesothelioma and adenocarcinoma. However, false positive reactions can occur so results must be interpreted with the utmost caution. This antibody may be useful in the differentiation of non-small cell carcinomas from small cell carcinomas of the lung. The combined use of anti-TAG-72 and anti-GCDFP-15 is valuable in the diagnosis of apocrine carcinoma.

Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. See the CF® Dye Brochure for more information. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Stock status: Because Biotium offers a large number of antibody and conjugation options, primary antibody conjugates may be made to order. Typical lead times are up to one week for CF® dye and biotin conjugates, and up to 2-3 weeks for fluorescent protein and enzyme conjugates. Please email order@biotium.com to inquire about stock status and lead times before placing your order.

 Catalog number key for antibody number 0734, Anti-CA72.4 (B72.3 CA72/733) The prefix indicates conjugation, followed by the antibody number and size suffix.

Antibody # prefixConjugationEx/EmConcentrationStorage Buffer
BNC04CF®405S404/431 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC05CF®405M408/452 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC88CF®488A490/515 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC43CF®543541/560 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC55CF®555555/565 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC68CF®568562/583 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC94CF®594593/614 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC40CF®640R642/662 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC47CF®647650/665 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC61CF®660R663/682 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC80CF®680681/698 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC81CF®680R680/701 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC70CF®770770/797 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCRR-PE (PE)496, 546, 565/578 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCAAPC650/660 nnm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCPPerCP482/677 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCBBiotinN/A0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCAPAlkaline PhosphataseN/A0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCHHorseradish PeroxidaseN/A0.1 mg/mL PBS, 0.05% BSA, no azide
BNUBPurified, with BSA N/A0.2 mg/mL PBS, 0.05% BSA, 0.05% azide
BNUMPurified, BSA-freeN/A1 mg/mL PBS, no BSA, no azide

References

Lottich SC et. al. Breast Cancer Research and Treatment, 1985, 6(1):49-56. | Thor A et. al. Cancer Research, 1986, 46(6):3118-24

 

You may also like…